Latest Tokyo Brief coverage on CHUGAI PHARMACEUTICAL CO., LTD., tracking filings, financial news, and market signals from Japan.
TSE:4519
Chugai Pharmaceutical's nine-month revenue rose 17.2%, with domestic sales helped by wholesaler shipments brought forward ahead of an ERP launch, yet full-year Core guidance of 6.9% revenue growth stays unchanged.
An interim analysis of Chugai's Phase 2 obesity trial for the myostatin antibody emugrobart found the targeted weight loss unlikely, so Roche is exiting the program entirely and is set to return all license rights to Chugai, which is now preparing, but has not decided, a possible return to spinal muscular atrophy development.
Overseas shipments to majority owner Roche and royalty income from a licensed itch drug pushed Chugai's core profit up 23% in the first half, even as Japan's drug-price cuts dented older cancer medicines at home.
Hemlibra shipments to majority owner Roche and a sharp jump in Nemluvio exports to Galderma drove Chugai's core operating profit up 21% in the first half, while Japan's price controls kept domestic growth modest and management left its full-year guidance exactly where it stood in January.
Current holdings disclosed by tracked funds.